BridgeMD
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
EU CTIS ID: 2025-523123-22-00
What this study is testing
To demonstrate whether orforglipron is superior to placebo in reducing the risk for major CV events.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have heart disease, kidney disease, or both
You likely can't join if
- Have type 1 diabetes
- Have had a serious heart condition within 60 days of screening
- Have New York Heart Association Functional Classification Class IV heart failure
The study team makes the final eligibility decision.
Where it's taking place
- New Zealand
- South Africa
- Taiwan
- Australia
- Thailand
- Ukraine
- United Kingdom
- Serbia
- Israel
- Argentina
- Brazil
- Mexico
- China
- Korea, Republic of
- Japan
- Philippines
- Malaysia
- Colombia
- Canada
- Tunisia
+ 2 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Zealand; South Africa; Taiwan; Australia; Thailand; Ukraine and 16 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.